BSR_12_0175_A5_S64
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- ANGIOGENESIS+0.350
- ALLOGRAFT_REJECTION+0.320
- INTERFERON_GAMMA_RESPONSE+0.320
- APICAL_SURFACE+0.300
- WNT_BETA_CATENIN_SIGNALING+0.290
- HEDGEHOG_SIGNALING+0.280
- KRAS_SIGNALING_UP+0.240
- INTERFERON_ALPHA_RESPONSE+0.230
- IL6_JAK_STAT3_SIGNALING+0.220
Top 10 suppressed
- MYC_TARGETS_V1-0.590
- OXIDATIVE_PHOSPHORYLATION-0.570
- MYC_TARGETS_V2-0.520
- FATTY_ACID_METABOLISM-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.410
- ADIPOGENESIS-0.400
- MTORC1_SIGNALING-0.400
- CHOLESTEROL_HOMEOSTASIS-0.350
- PROTEIN_SECRETION-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-8628-01A-11R-2403-07 | — | cohortSQ1 | 0.884 |
| 2 | 0056507f-a296-4148-bc9f-a831249c7973 | — | — | 0.881 |
| 3 | TCGA-55-7574-01A-11R-2039-07 | — | cohortMD2 | 0.880 |
| 4 | SRR1516085 | — | — | 0.879 |
| 5 | 5af57d46-5acb-424a-9675-ee3dd20db062 | — | — | 0.873 |
| 6 | TCGA-93-A4JQ-01A-11R-A24X-07 | — | cohortA1 | 0.872 |
| 7 | C3N-03233 | — | cohortA1 | 0.871 |
| 8 | 156a3def-5866-4be4-ad0b-61b957d5b6eb | — | — | 0.865 |
| 9 | TCGA-AQ-A7U7-01A-22R-A352-07 | — | D | 0.865 |
| 10 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |